A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy
Top Cited Papers
Open Access
- 21 July 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 142 (3), 217-229
- https://doi.org/10.1161/circulationaha.120.047235
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death (SCD) in children and young adults. Our objective was to develop and validate a SCD risk prediction model in pediatric HCM to guide SCD prevention strategies. Methods: In an international multi-center observational cohort study, phenotype-positive patients with isolated HCM Results: Overall, 572 patients met eligibility criteria with 2855 patient-years of follow-up. The 5-year cumulative proportion of SCD events was 9.1% (14 SCD, 25 resuscitated SCA, 14 aborted SCD). Risk predictors included age at diagnosis, documented non-sustained ventricular tachycardia, unexplained syncope, septal diameter z-score, LV posterior wall diameter z-score, LA diameter z-score, peak LV outflow tract (LVOT) gradient, and presence of a pathogenic variant. Unlike adults, LVOT gradient had an inverse association, and family history of SCD had no association with SCD. Clinical and clinical/genetic models were developed to predict 5-year freedom from SCD. Both models adequately discriminated patients with and without SCD events with a c-statistic of 0.75 and 0.76 respectively and demonstrated good agreement between predicted and observed events in the primary and validation cohorts (validation c-statistic 0.71 and 0.72 respectively). Conclusions:Our study provides a validated SCD risk prediction model with over 70% prediction accuracy and incorporates risk factors that are unique to pediatric HCM. An individualized risk prediction model has the potential to improve the application of clinical practice guidelines and shared decision-making for ICD insertion. Clinical Trial Registration:URL: https://clinicaltrials.gov Unique Identifier: NCT04036799This publication has 44 references indexed in Scilit:
- Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic CardiomyopathyJournal of the American College of Cardiology, 2013
- 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsJournal of the American College of Cardiology, 2011
- Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic CardiomyopathyCirculation: Cardiovascular Genetics, 2009
- Multiple Mutations in Genetic Cardiovascular DiseaseCirculation: Cardiovascular Genetics, 2009
- Genetic Determinants of Sudden Cardiac DeathCirculation, 2008
- Results of a Multicenter Retrospective Implantable Cardioverter-Defibrillator Registry of Pediatric and Congenital Heart Disease PatientsJournal of the American College of Cardiology, 2008
- Variable selection under multiple imputation using the bootstrap in a prognostic studyBMC Medical Research Methodology, 2007
- Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathyHeart, 2007
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young AdultsCirculation, 1995